证券日报网讯 1月9日，特一药业在互动平台回答投资者提问时表示，公司核心产品止咳宝片具备显著 的竞争壁垒：一是工艺技术优势。公司采用先进提取工艺与定量测定技术，保障药品质量稳定可控。并 围绕止咳宝片，就中药组合物、制备方法、成分检测等方面申请多项发明专利，且均已获得发明专利证 书，形成了完善的专利保护体系。二是品牌优势。止咳宝片具有百年历史，市场认可度高，拥有忠实用 户群体。三是疗效优势，临床验证止咳宝片对虚寒型和痰湿型咳喘治疗效果最好，总有效率分别是 100%及95%，毒副作用低、见效快。目前，公司正以止咳宝片为核心构建"1+N"产品矩阵，持续丰富产 品线，进一步巩固和提升公司核心竞争力。 （文章来源：证券日报） ...

证券日报网讯 1月9日，特一药业在互动平台回答投资者提问时表示，公司核心产品止咳宝片具有百年 历史，具有"宣肺祛痰、止咳平喘"之功效。 （文章来源：证券日报） ...

证券日报网讯 1月9日，特一药业在互动平台回答投资者提问时表示，随着公司营销变革稳步推进，经 营成效持续显现。2025年前三季度，公司实现营业总收入6.92亿元，同比增长51.86%；实现归属于上市 公司股东的净利润6521.71万元，同比增长985.18%。核心产品"特一"牌止咳宝片的销售稳步恢复，前三 季度销量已恢复至2023年同期的64%，线上业务拓展也取得了积极成效。基于前三季度的经营态势，公 司2025年年度经营情况符合内部规划预期。当前，公司财务部门正有序开展年度财务核算工作。后续， 公司将严格按照相关规定，结合财务核算结果及时履行信息披露义务。 （编辑 袁冠琳） ...

格隆汇1月9日丨特一药业(002728.SZ)在投资者互动平台表示，公司目前暂未布局"中药+脑机接口"相关 业务，但会持续关注该领域技术发展动态。未来若有相关业务规划，公司将严格按照信息披露规则及时 履行公告义务。 ...

格隆汇1月9日丨特一药业(002728.SZ)在投资者互动平台表示，公司目前无高压氧舱相关产品。 ...

特此公告。 特一药业集团股份有限公司 董事会 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于2025年5月21日召开第五届董事会第三 十二次会议，审议通过了《关于使用可转债部分闲置募集资金暂时补充流动资金的议案》，为了有效提 高募集资金的使用效率，减少财务费用，降低运营成本，维护公司和股东利益，在确保公司可转换公司 债券募集资金投资项目按进度实施的前提下，同意公司使用不超过人民币2,500万元可转债闲置募集资 金暂时补充流动资金，董事会审议通过后，自首次办理暂时补充流动资金之日起，不超过12个月，到期 前归还至募集资金专用账户。具体内容详见公司于2025年5月22日刊登于法定媒体及巨潮资讯网 （http://www.cninfo.com.cn/）上的《关于使用可转债部分闲置募集资金暂时补充流动资金的公告》（公 告编号：2025-033）。 在使用可转债部分闲置募集资金暂时补充流动资金期间，公司通过合理安排，资金运作良好。2026年1 月6日，公司将上 ...

关于提前归还可转债部分暂时补充流动资金的募集资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 截至目前，公司已累计归还 1,100 万元资金至可转债募集资金专用账户，剩余暂时 补充流动资金的 1,400 万元闲置募集资金将在到期之前归还。在此期间如遇可转债募集 资金专用账户余额不能满足募集资金正常支付的情况，公司将根据实际需要将已补充流 动资金的募集资金提前归还至可转债募集资金专用账户，届时公司将及时履行信息披露 义务。 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2025 年 5 月 21 日召开第五届董事会第三十二次会议，审议通过了《关于使用可转债部分闲置募集资 金暂时补充流动资金的议案》，为了有效提高募集资金的使用效率，减少财务费用，降 低运营成本，维护公司和股东利益，在确保公司可转换公司债券募集资金投资项目按进 度实施的前提下，同意公司使用不超过人民币 2,500 万元可转债闲置募集资金暂时补充 流动资金，董事会审议通过后，自首次办理暂时补充流动资金之日起，不超过 12 个月， 到期前归还至募集资金专用账户。具体内容详见公司 ...

Group 1: Company Announcements - Zhongwei Company plans to acquire 64.69% equity of Hangzhou Zhonggui through a combination of share issuance and cash payment, aiming to enhance its capabilities in CMP equipment and solutions [1] - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion RMB for employee stock ownership plans or equity incentives, with a maximum repurchase price of 86.96 RMB per share [2] - ZaiJing Pharmaceutical has reached a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, receiving an upfront payment of 100 million USD [3] - Tianci Materials expects a net profit increase of 127% to 231% for 2025, driven by significant growth in lithium-ion battery material sales [4] - Meike Home plans to acquire 100% equity of Shenzhen Wande Technology through share issuance and cash payment, with stock resuming trading on January 5, 2026 [6][7] - ST KeliDa is planning a change in control, with stock suspension starting January 5, 2026, due to the transfer of 100% equity of its controlling shareholder [8] - Xinzhou Bang intends to invest approximately 260 million USD in a lithium-ion battery materials project in Saudi Arabia, enhancing its global capacity and supply chain [9] Group 2: Financial Performance - Kid's King anticipates a net profit increase of 51.72% to 82.06% for 2025 [9] - Guangku Technology expects a net profit growth of 152% to 172% for 2025 [9] Group 3: Mergers and Acquisitions - Xidi Micro plans to acquire 100% equity of Chengxin Micro for 310 million RMB [9] - Haili Biological's subsidiary intends to acquire 51% equity of seven dental chain companies for 61.2 million RMB [9]

Group 1 - The flu epidemic in China is at a high level, primarily driven by the H3N2 strain, with increased transmission risk due to upcoming population movements during the New Year holiday [1] - Demand for antiviral and symptomatic medications has surged, with a reported over 500% increase in flu-related drug purchases on Alibaba Health and over 100% increase in orders for traditional Chinese medicine on Meituan [1] - The pharmaceutical industry is responding effectively across the supply chain, from vaccine production to drug distribution, indicating a well-coordinated effort to manage the public health challenge [1][2] Group 2 - Vaccine companies are ramping up production, with Hualan Vaccine reporting 55 batches of flu vaccine issued since November, reflecting increased public willingness to get vaccinated [2] - Diagnostic companies like Dian Diagnostics and Kingmed Diagnostics are seeing increased business, supporting the trend of testing before treatment, which enhances rational drug use [2] - The treatment landscape is diversifying, with both chemical and traditional Chinese medicines being utilized, indicating a shift in market dynamics [3][5] Group 3 - Traditional Chinese medicine is gaining traction, with companies like China Resources Sanjiu and Kangyuan Pharmaceutical seeing strong growth in their antiviral product lines [5] - The distribution sector is crucial, with companies like Yiyigou ensuring rapid delivery of essential medications during peak demand periods [5] - The clinical relevance of traditional Chinese medicine is increasing, supported by government policies that endorse its use in flu treatment, leading to a rise in evidence-based research [6][9] Group 4 - Companies are focusing on clinical research to validate the efficacy of traditional Chinese medicines, with Kangyuan Pharmaceutical conducting head-to-head trials against conventional drugs [7][9] - The competitive landscape in the respiratory system traditional Chinese medicine market is diverse, with companies like China Resources Sanjiu and Yiling Pharmaceutical leveraging brand strength and market recognition [9] - As the industry moves towards evidence-based medicine, companies with strong research capabilities and clinical data are likely to capture more market opportunities [9]

证券日报网讯12月26日，特一药业（002728）在互动平台回答投资者提问时表示，公司在药物创新研究 方面，持续推行中成药和化学药研发双向并举进行：在中成药方面：加强对现有中成药的传承和开发， 通过临床研究或真实世界研究，对特色中成药产品进行二次开发，推动公司特色中药品种(含止咳宝 片、皮肤病血毒丸、降糖舒丸等)成长为中成药大品种，以创新促质量提升，提高"特一"品牌影响力， 进而提升产品的市场竞争力；同时，积极抓住中药产业发展的机会，加强与相关院所合作，开发中药创 新药；在化学药方面：开展"原料药+制剂"一体化创新研究，对重大疾病治疗药物进行前沿化调研， 以"原料药+制剂"关联的模式开展制剂和原料的研发，提高协同效应。 ...